PLRX

Pliant TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.01

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$1.15

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.55

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-28

AI commentary

Cautious monitoring setup. The August 11 company update is positive on FORTIFY enrollment and platform progress, but verified consensus surprise, analyst revisions, and attributed post-print market reaction are unavailable. Low coverage and binary clinical risk cap conviction.

RankAlpha Sentiment Codex - 2026-08-28

Open full AI memo

Evidence flagged

small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31catalystCash balance provides financing flexibilityHigh impact

The Q2 2026 10-Q reported $159.6 million of cash, cash equivalents, and short-term investments as of June 30, 2026. This provides balance-sheet flexibility but does not establish a precise runway or remove dilution risk. [#10-Q-2026-08-11]

2026-12-31catalystIntegrin-targeted siRNA platform proof-of-concept milestoneHigh impact

Pliant said preclinical proof-of-concept studies for its integrin-targeted siRNA delivery platform are ongoing and plans to provide additional detail, including initial treatment indications, in the second half of 2026. This remains unvalidated long-horizon optionality. [#PR-EARNINGS-2026-08-11]

2027-12-31eventFORTIFY enrollment and interim-data pathHigh impact

Pliant reported strong, ahead-of-schedule enrollment in the Phase 1b FORTIFY expansion trial of PLN-101095, with interim data expected in 2027. [#PR-EARNINGS-2026-08-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-28 • Updated nightlySource: Internal modelMethodology